ALLK News and Press, Allakos Inc. From 11/02/20

REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroentero...

REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten pu...

For Q3, Allakos (ALLK) estimates net loss to be between $40-$50M vs. $21.7M in year ago quarter, an increase of $18.3-$28.3M.The company estimates cash, cash equivalents and investments in marketable securities to be $419.8M.Q3 earnings are scheduled for Nov.9 release, before market opens.Sha...

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months...

Allakos (ALLK) intends to offer $250M of shares in an underwritten public offering. Underwriters have an option to purchase up to $37.5M of additional shares.Price and number of shares are yet to be decided. For further details see: Allakos initiates equity offering

Allakos (ALLK) has announced results from a Phase 1 study of subcutaneously ((SC)) administered lirentelimab (AK002) in healthy volunteers. Based on these results, Allakos intends to investigate monthly dosing of the SC formulation of lirentelimab in patients with eosinophilic gastritis,...

-- 45 % (18 1 / 405 ) of symptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis -- -- Management to host con...

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference call and webcast today at 8:00 am ET -- R...

Allakos ([[ALLK]] +7.9%) has announced the publication of results from Phase 2 study of lirentelimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis in the New England Journal of Medicine.All AK002 dose arms showed clinically meaningful and statis...

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-bl...